Last 12 months
Inside the activity.
4 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 4 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 19:05 UTC |
LEE WILLIS CDirector · CEO
|
PurchaseCommon stock, $0.001 par value | 100,000 | $0.05 | $5,000.00 |
DisclosureSEC source: 0001193125-26-380023 · ownership.xml · nonDerivative · entry 8 LEE WILLIS C · CIK 0001517775 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Fidelity Roth IRA FBO Willis C. Lee Disclosed balance after: 690,167 F6 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.046 to $0.05, inclusive. Read SEC document |
| August 28, 2026 Filed Sep 2, 2026 19:05 UTC |
LEE WILLIS CDirector · CEO
|
PurchaseCommon stock, $0.001 par value | 94,767 | $0.06 | $5,686.02 |
DisclosureSEC source: 0001193125-26-380023 · ownership.xml · nonDerivative · entry 7 LEE WILLIS C · CIK 0001517775 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Fidelity Roth IRA FBO Willis C. Lee Disclosed balance after: 590,167 F5 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.050 to $0.075, inclusive. Read SEC document |
| August 27, 2026 Filed Sep 2, 2026 19:05 UTC |
LEE WILLIS CDirector · CEO
|
PurchaseCommon stock, $0.001 par value | 50,000 | $0.05 | $2,500.00 |
DisclosureSEC source: 0001193125-26-380023 · ownership.xml · nonDerivative · entry 6 LEE WILLIS C · CIK 0001517775 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Fidelity Roth IRA FBO Willis C. Lee Disclosed balance after: 495,400 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.044 to $0.051, inclusive. Read SEC document |
| August 25, 2026 Filed Sep 2, 2026 19:05 UTC |
LEE WILLIS CDirector · CEO
|
PurchaseCommon stock, $0.001 par value | 46,000 | $0.04 | $1,840.00 |
DisclosureSEC source: 0001193125-26-380023 · ownership.xml · nonDerivative · entry 5 LEE WILLIS C · CIK 0001517775 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Fidelity Roth IRA FBO Willis C. Lee Disclosed balance after: 445,400 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.034 to $0.039, inclusive. Read SEC document |
| August 29, 2025 Filed Sep 2, 2026 19:05 UTC |
LEE WILLIS CDirector · CEO
|
PurchaseCommon stock, $0.001 par value | 170,000 | $0.01 | $1,700.00 |
DisclosureSEC source: 0001193125-26-380023 · ownership.xml · nonDerivative · entry 4 LEE WILLIS C · CIK 0001517775 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Fidelity Roth IRA FBO Willis C. Lee Disclosed balance after: 275,400 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.0109 to $0.011, inclusive. Read SEC document |
| May 30, 2025 Filed Sep 2, 2026 19:05 UTC |
LEE WILLIS CDirector · CEO
|
PurchaseCommon stock, $0.001 par value | 70,000 | $0.02 | $1,400.00 |
DisclosureSEC source: 0001193125-26-380023 · ownership.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Fidelity Roth IRA FBO Willis C. Lee Disclosed balance after: 229,400 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.01 to $0.02, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1), footnote (2), footnote (3), footnote (4), footnote (5) and footnote (6). Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 15:40 UTC |
Lim Seah H.Director
|
PurchaseCommon stock, $0.001 par value | 20,000 | $0.04 | $800.00 |
DisclosureSEC source: 0000950170-24-107658 · ownership.xml · nonDerivative · entry 1 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,606,626 Read SEC document |
| February 29, 2024 Filed Feb 29, 2024 23:11 UTC |
LEE WILLIS CDirector · Co-President & COO
|
PurchaseCommon stock, $0.001 par value | 77,000 | $0.13 | $10,010.00 |
DisclosureSEC source: 0001209191-24-004124 · doc4.xml · nonDerivative · entry 4 LEE WILLIS C · CIK 0001517775 · Director · Co-President & COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fidelity Roth IRA FBO Willis C. Lee Disclosed balance after: 159,400 Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 23:11 UTC |
LEE WILLIS CDirector · Co-President & COO
|
PurchaseCommon stock, $0.001 par value | 15,000 | $0.12 | $1,800.00 |
DisclosureSEC source: 0001209191-24-004124 · doc4.xml · nonDerivative · entry 3 LEE WILLIS C · CIK 0001517775 · Director · Co-President & COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fidelity Roth IRA FBO Willis C. Lee Disclosed balance after: 82,400 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.12 to $0.13, inclusive. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:11 UTC |
LEE WILLIS CDirector · Co-President & COO
|
PurchaseCommon stock, $0.001 par value | 10,000 | $0.13 | $1,300.00 |
DisclosureSEC source: 0001209191-24-004124 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Co-President & COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fidelity Roth IRA FBO Willis C. Lee Disclosed balance after: 67,400 Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 23:11 UTC |
LEE WILLIS CDirector · Co-President & COO
|
PurchaseCommon stock, $0.001 par value | 13,200 | $0.12 | $1,584.00 |
DisclosureSEC source: 0001209191-24-004124 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Co-President & COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fidelity Roth IRA FBO Willis C. Lee Disclosed balance after: 57,400 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.12 to $0.13, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:40 UTC |
Zwicker Ian HarveyDirector
|
GrantOptions · Derivative | 100,000 | $0.15 Strike: $0.15 | $15,000.00 |
DisclosureSEC source: 0001209191-24-002819 · doc4.xml · derivative · entry 1 Zwicker Ian Harvey · CIK 0001642012 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-01-31 F1 · derivative.exercise_date: The options vest in four equal installments as of the last day of each quarter beginning on March 31, 2024 Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:39 UTC |
ZEN Wei PeuDirector
|
GrantOptions · Derivative | 100,000 | $0.15 Strike: $0.15 | $15,000.00 |
DisclosureSEC source: 0001209191-24-002815 · doc4.xml · derivative · entry 1 ZEN Wei Peu · CIK 0001746204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-01-31 F1 · derivative.exercise_date: The options vest in four equal installments as of the last day of each quarter beginning on March 31, 2024 Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:38 UTC |
Lim Seah H.Director
|
GrantOptions · Derivative | 100,000 | $0.15 Strike: $0.15 | $15,000.00 |
DisclosureSEC source: 0001209191-24-002811 · doc4.xml · derivative · entry 1 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-01-31 F1 · derivative.exercise_date: The options vest in four equal installments as of the last day of each quarter beginning on March 31, 2024 Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:35 UTC |
Sekulich GeorgeDirector · Co-President & CCO
|
GrantOptions · Derivative | 200,000 | $0.15 Strike: $0.15 | $30,000.00 |
DisclosureSEC source: 0001209191-24-002798 · doc4.xml · derivative · entry 1 Sekulich George · CIK 0001896627 · Director · Co-President & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-01-31 Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:37 UTC |
Stark Charles WilliamCSO & EVP Clinical Development
|
GrantOptions · Derivative | 200,000 | $0.15 Strike: $0.15 | $30,000.00 |
DisclosureSEC source: 0001209191-24-002804 · doc4.xml · derivative · entry 1 Stark Charles William · CIK 0001901666 · CSO & EVP Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-01-31 Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:34 UTC | GrantOptions · Derivative | 200,000 | $0.15 Strike: $0.15 | $30,000.00 |
DisclosureSEC source: 0001209191-24-002795 · doc4.xml · derivative · entry 1 NAGASAKI YASUSHI · CIK 0001517916 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-01-31 Read SEC document |
|
| February 01, 2024 Filed Feb 5, 2024 21:32 UTC |
LEE WILLIS CDirector · Co-President & COO
|
GrantOptions · Derivative | 200,000 | $0.15 Strike: $0.15 | $30,000.00 |
DisclosureSEC source: 0001209191-24-002790 · doc4.xml · derivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Co-President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-01-31 Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 16:34 UTC |
Lim Seah H.Director
|
SaleCommon stock, $0.001 par value | 32,500 | $0.05 | $1,625.00 |
DisclosureSEC source: 0001209191-23-059399 · doc4.xml · nonDerivative · entry 1 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,586,626 Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:44 UTC |
Lim Seah H.Director
|
OtherPromissory Note due 9/16/2025 · Derivative | 240,000 | Not disclosed Strike: $0.29 | Not disclosed |
DisclosureSEC source: 0001209191-23-059268 · doc4.xml · derivative · entry 7 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 240,000 shares Expires not disclosed F3 · kind: Promissory Note due 9/16/2025 surrendered for cancellation in exchange for shares of common stock referred to in footnote (1) above. F4 · shares: Represent shares previously issuable upon maturity of the Promissory Note due 9/16/2025. F3 · price: Promissory Note due 9/16/2025 surrendered for cancellation in exchange for shares of common stock referred to in footnote (1) above. F3 · derivative.exercise_date: Promissory Note due 9/16/2025 surrendered for cancellation in exchange for shares of common stock referred to in footnote (1) above. F3 · derivative.expiration_date: Promissory Note due 9/16/2025 surrendered for cancellation in exchange for shares of common stock referred to in footnote (1) above. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:44 UTC |
Lim Seah H.Director
|
OtherCommon stock, $0.001 par value | 4,447,426 | $0.29 | $1,289,753.54 |
DisclosureSEC source: 0001209191-23-059268 · doc4.xml · nonDerivative · entry 6 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,619,126 F2 · kind: The shares shown were issued in exchange for principal and accrued interest under the promissory note of the Issuer held by the reporting person referred to in footnote (2), below, which promissory note was surrendered by the reporting person for cancellation. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:44 UTC |
Lim Seah H.Director
|
SaleCommon stock, $0.001 par value | 6,000 | $0.11 | $660.00 |
DisclosureSEC source: 0001209191-23-059268 · doc4.xml · nonDerivative · entry 5 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,700 Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:40 UTC |
ZEN Wei PeuDirector
|
OtherCommon stock, $0.001 par value | 3,760,983 | $0.29 | $1,090,685.07 |
DisclosureSEC source: 0001209191-23-059265 · doc4.xml · nonDerivative · entry 1 ZEN Wei Peu · CIK 0001746204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,768,817 F1 · kind: The shares shown were issued in exchange for principal and accrued interest under the promissory note of the Issuer held by the reporting person referred to in footnote (2), below, which promissory note was surrendered by the reporting person for cancellation. Read SEC document |
| November 30, 2023 Filed Dec 5, 2023 01:33 UTC |
LEE WILLIS CDirector · COO
|
PurchaseCommon stock, $0.001 par value | 7,417 | $0.12 | $890.04 |
DisclosureSEC source: 0001209191-23-057328 · doc4.xml · nonDerivative · entry 6 LEE WILLIS C · CIK 0001517775 · Director · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 395,124 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.11 to $0.13, inclusive. Read SEC document |
| November 30, 2023 Filed Jan 3, 2024 21:59 UTC Amendment |
LEE WILLIS CDirector · COO
|
PurchaseCommon stock, $0.001 par value | 59,400 | $0.12 | $7,128.00 |
DisclosureSEC source: 0001209191-24-000442 · doc4a.xml · nonDerivative · entry 6 LEE WILLIS C · CIK 0001517775 · Director · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 395,124 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.11 to $0.13, inclusive. Read SEC document |
| November 29, 2023 Filed Dec 5, 2023 01:33 UTC |
LEE WILLIS CDirector · COO
|
PurchaseCommon stock, $0.001 par value | 4,325 | $0.12 | $519.00 |
DisclosureSEC source: 0001209191-23-057328 · doc4.xml · nonDerivative · entry 5 LEE WILLIS C · CIK 0001517775 · Director · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,724 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.11 to $0.13, inclusive. Read SEC document |
| November 29, 2023 Filed Jan 3, 2024 21:59 UTC Amendment |
LEE WILLIS CDirector · COO
|
PurchaseCommon stock, $0.001 par value | 36,000 | $0.12 | $4,320.00 |
DisclosureSEC source: 0001209191-24-000442 · doc4a.xml · nonDerivative · entry 5 LEE WILLIS C · CIK 0001517775 · Director · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,724 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.11 to $0.13, inclusive. Read SEC document |
| November 28, 2023 Filed Dec 5, 2023 01:33 UTC |
LEE WILLIS CDirector · COO
|
PurchaseCommon stock, $0.001 par value | 1,470 | $0.12 | $176.40 |
DisclosureSEC source: 0001209191-23-057328 · doc4.xml · nonDerivative · entry 4 LEE WILLIS C · CIK 0001517775 · Director · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,724 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.12 to $0.13, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (2) and (3) to this Form 4. Read SEC document |
| November 28, 2023 Filed Jan 3, 2024 21:59 UTC Amendment |
LEE WILLIS CDirector · COO
|
PurchaseCommon stock, $0.001 par value | 12,000 | $0.12 | $1,440.00 |
DisclosureSEC source: 0001209191-24-000442 · doc4a.xml · nonDerivative · entry 4 LEE WILLIS C · CIK 0001517775 · Director · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,724 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.12 to $0.13, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (2) and (3) to this Form 4. Read SEC document |
| November 14, 2023 Filed Dec 5, 2023 01:33 UTC |
LEE WILLIS CDirector · COO
|
PurchaseCommon stock, $0.001 par value | 132 | $0.12 | $15.84 |
DisclosureSEC source: 0001209191-23-057328 · doc4.xml · nonDerivative · entry 3 LEE WILLIS C · CIK 0001517775 · Director · COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fidelity Roth IRA FBO Willis C. Lee Disclosed balance after: 44,200 Read SEC document |
| November 14, 2023 Filed Jan 3, 2024 21:59 UTC Amendment |
LEE WILLIS CDirector · COO
|
PurchaseCommon stock, $0.001 par value | 1,100 | $0.12 | $132.00 |
DisclosureSEC source: 0001209191-24-000442 · doc4a.xml · nonDerivative · entry 3 LEE WILLIS C · CIK 0001517775 · Director · COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fidelity Roth IRA FBO Willis C. Lee Disclosed balance after: 44,200 Read SEC document |
| September 05, 2023 Filed Dec 20, 2023 00:44 UTC |
Lim Seah H.Director
|
PurchaseCommon stock, $0.001 par value | 1,700 | $0.15 | $255.00 |
DisclosureSEC source: 0001209191-23-059268 · doc4.xml · nonDerivative · entry 4 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,700 Read SEC document |
| August 31, 2023 Filed Dec 5, 2023 01:33 UTC |
LEE WILLIS CDirector · COO
|
PurchaseCommon stock, $0.001 par value | 900 | $0.15 | $135.00 |
DisclosureSEC source: 0001209191-23-057328 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fidelity Roth IRA FBO Willis C. Lee Disclosed balance after: 43,100 Read SEC document |
| August 31, 2023 Filed Jan 3, 2024 21:59 UTC Amendment |
LEE WILLIS CDirector · COO
|
PurchaseCommon stock, $0.001 par value | 6,000 | $0.15 | $900.00 |
DisclosureSEC source: 0001209191-24-000442 · doc4a.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fidelity Roth IRA FBO Willis C. Lee Disclosed balance after: 43,100 Read SEC document |
| August 30, 2023 Filed Dec 20, 2023 00:44 UTC |
Lim Seah H.Director
|
PurchaseCommon stock, $0.001 par value | 20,000 | $0.15 | $3,000.00 |
DisclosureSEC source: 0001209191-23-059268 · doc4.xml · nonDerivative · entry 3 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,000 Read SEC document |
| August 25, 2023 Filed Dec 5, 2023 01:33 UTC |
LEE WILLIS CDirector · COO
|
PurchaseCommon stock, $0.001 par value | 1,365 | $0.21 | $286.65 |
DisclosureSEC source: 0001209191-23-057328 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fidelity Roth IRA FBO Willis C. Lee Disclosed balance after: 37,100 Read SEC document |
| August 25, 2023 Filed Dec 20, 2023 00:44 UTC |
Lim Seah H.Director
|
PurchaseCommon stock, $0.001 par value | 92,100 | $0.27 | $24,867.00 |
DisclosureSEC source: 0001209191-23-059268 · doc4.xml · nonDerivative · entry 2 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,000 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.20 to $0.27, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). Read SEC document |
| August 25, 2023 Filed Jan 3, 2024 21:59 UTC Amendment |
LEE WILLIS CDirector · COO
|
PurchaseCommon stock, $0.001 par value | 6,500 | $0.21 | $1,365.00 |
DisclosureSEC source: 0001209191-24-000442 · doc4a.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fidelity Roth IRA FBO Willis C. Lee Disclosed balance after: 37,100 Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 17:23 UTC |
LEE WILLIS CDirector · COO
|
PurchaseCommon stock, $0.001 par value | 28,700 | $0.29 | $8,323.00 |
DisclosureSEC source: 0001209191-23-033573 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · COO 10b5-1 filing: No plan indicated Ownership: Indirect · By Fidelity Roth IRA FBO Willis C. Lee Disclosed balance after: 30,600 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.28 to $0.32, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 16:40 UTC |
ZEN Wei PeuDirector
|
PurchaseConvertible Promissory Note dated 2023-01-18 · Derivative | 2,000,000 | $0.50 Strike: $0.50 | $1,000,000.00 |
DisclosureSEC source: 0001209191-23-004167 · doc4.xml · derivative · entry 1 ZEN Wei Peu · CIK 0001746204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2025-01-17 Read SEC document |
| January 18, 2023 Filed Dec 20, 2023 00:40 UTC |
ZEN Wei PeuDirector
|
OtherConvertible Promissory Note dated 2023-01-18 · Derivative | 2,000,000 | $0.50 Strike: $0.50 | $1,000,000.00 |
DisclosureSEC source: 0001209191-23-059265 · doc4.xml · derivative · entry 3 ZEN Wei Peu · CIK 0001746204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000,000 shares Expires not disclosed F3 · kind: The Convertible Promissory Note dated 2023-01-18 was surrendered to the Issuer for cancellation in exchange for the shares referred to in footnote (1), above. F4 · shares: Represent shares previously issuable upon conversion of the Convertible Promissory Note. F3 · derivative.exercise_date: The Convertible Promissory Note dated 2023-01-18 was surrendered to the Issuer for cancellation in exchange for the shares referred to in footnote (1), above. F3 · derivative.expiration_date: The Convertible Promissory Note dated 2023-01-18 was surrendered to the Issuer for cancellation in exchange for the shares referred to in footnote (1), above. Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 19:36 UTC |
Zwicker Ian HarveyDirector
|
GrantOptions · Derivative | 100,000 | $4.50 Strike: $4.50 | $450,000.00 |
DisclosureSEC source: 0001209191-23-003472 · doc4.xml · derivative · entry 1 Zwicker Ian Harvey · CIK 0001642012 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-11 F1 · derivative.exercise_date: The options vest in four equal installments as of the last day of each quarter beginning on March 31, 2023 Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 19:35 UTC |
ZEN Wei PeuDirector
|
GrantOptions · Derivative | 100,000 | $4.50 Strike: $4.50 | $450,000.00 |
DisclosureSEC source: 0001209191-23-003470 · doc4.xml · derivative · entry 1 ZEN Wei Peu · CIK 0001746204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-11 F1 · derivative.exercise_date: The options vest in four equal installments as of the last day of each quarter beginning on March 31, 2023 Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 19:32 UTC |
Stark Charles WilliamSVP, Clinical Development
|
GrantOptions · Derivative | 100,000 | $4.50 Strike: $4.50 | $450,000.00 |
DisclosureSEC source: 0001209191-23-003466 · doc4.xml · derivative · entry 1 Stark Charles William · CIK 0001901666 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-11 F1 · derivative.exercise_date: The options vest as to one-third of the option shares on the 12-month anniversary of the grant date and as to the remaining two-thirds of the option shares in 24 equal monthly installments as of the end of each month after such anniversary. Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 19:34 UTC |
Lim Seah H.Director
|
GrantOptions · Derivative | 100,000 | $4.50 Strike: $4.50 | $450,000.00 |
DisclosureSEC source: 0001209191-23-003468 · doc4.xml · derivative · entry 1 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-11 F1 · derivative.exercise_date: The options vest in four equal installments as of the last day of each quarter beginning on March 31, 2023 Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 19:31 UTC |
Sekulich GeorgeCIO & SVP
|
GrantOptions · Derivative | 100,000 | $4.50 Strike: $4.50 | $450,000.00 |
DisclosureSEC source: 0001209191-23-003464 · doc4.xml · derivative · entry 1 Sekulich George · CIK 0001896627 · CIO & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-11 F1 · derivative.exercise_date: The options vest as to one-third of the option shares on the 12-month anniversary of the grant date and as to the remaining two-thirds of the option shares in 24 equal monthly installments as of the end of each month after such anniversary. Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 19:29 UTC | GrantOptions · Derivative | 150,000 | $4.50 Strike: $4.50 | $675,000.00 |
DisclosureSEC source: 0001209191-23-003462 · doc4.xml · derivative · entry 1 NAGASAKI YASUSHI · CIK 0001517916 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-01-11 F1 · derivative.exercise_date: The options vest as to one-third of the option shares on the 12-month anniversary of the grant date and as to the remaining two-thirds of the option shares in 24 equal monthly installments as of the end of each month after such anniversary. Read SEC document |
|
| January 12, 2023 Filed Jan 17, 2023 19:27 UTC |
LEE WILLIS CDirector · COO
|
GrantOptions · Derivative | 750,000 | $4.50 Strike: $4.50 | $3,375,000.00 |
DisclosureSEC source: 0001209191-23-003460 · doc4.xml · derivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2033-01-11 F1 · derivative.exercise_date: The options vest as to one-third of the option shares on the 12-month anniversary of the grant date and as to the remaining two-thirds of the option shares in 24 equal monthly installments as of the end of each month after such anniversary. Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 18:59 UTC |
Niihara YutakaDirector · Chairman and CEO · 10% owner
|
GrantWarrants (right to buy) · Derivative | 7,500,000 | $4.50 Strike: $4.50 | $33,750,000.00 |
DisclosureSEC source: 0001209191-23-003457 · doc4.xml · derivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500,000 shares Expires 2028-01-11 Read SEC document |
| January 12, 2023 Filed Jan 19, 2023 22:54 UTC Amendment |
LEE WILLIS CDirector · COO
|
GrantOptions · Derivative | 500,000 | $4.50 Strike: $4.50 | $2,250,000.00 |
DisclosureSEC source: 0001209191-23-004070 · doc4a.xml · derivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-01-11 F1 · derivative.exercise_date: The options vest as to one-third of the option shares on the 12-month anniversary of the grant date and as to the remaining two-thirds of the option shares in 24 equal monthly installments as of the end of each month after such anniversary. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.